Ecnoglutide vs Semaglutide
A cAMP-biased GLP-1 approved in China against the molecule that defined the class — same target, deliberately different signaling, very different regulatory reach.
Ecnoglutide
A cAMP-biased GLP-1 agonist engineered to reduce β-arrestin recruitment and desensitization; now NMPA-approved in China for type-2 diabetes and chronic weight management, but still unapproved in the US or EU.
Full Ecnoglutide evidence reviewSemaglutide
Wegovy / Ozempic
~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.
Full Semaglutide evidence reviewSide by side
| Ecnoglutide | Semaglutide | |
|---|---|---|
| Marketed for | Weight loss, type-2 diabetes | Weight loss, type-2 diabetes |
| Evidence grade | Clinical data | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | Phase 2/3 efficacy RCT, 2025 | STEP 1, NEJM 2021 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Both are approved, but not in the same places, and that is the whole practical difference: semaglutide is approved in the US and EU, while ecnoglutide’s approvals are China’s NMPA — type 2 diabetes in January 2026 and chronic weight management — with no US or EU authorization. Ecnoglutide is engineered to bias signaling toward cAMP and away from β-arrestin recruitment and receptor internalisation, which is a real pharmacological design choice rather than a marketing one. On weight the figures are closer than the reputations suggest but cannot be compared directly: a Chinese phase 3 in 664 adults without diabetes reported −13.2% at week 40 on 2.4 mg against +0.1% on placebo, versus semaglutide’s roughly 15% in STEP 1 over 68 weeks — different populations, durations and endpoints. Semaglutide’s real advantage is not the percentage; it is the outcomes record behind it.
Ecnoglutide fits if
You are following biased agonism as a design strategy, or you are in a market where ecnoglutide is actually approved and available.
Semaglutide fits if
You want the GLP-1 with the deepest evidence base and the widest approval, prescribable now.